Some search for battle, others are born into it ...

SAN DIEGO, Dec. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine ...

A Railway Express truck pulled up at a big yellow brick house on Chicago’s North Drake Avenue one morning last week, and as the deliveryman handed over a package, he said knowingly, “Here’s another ...

Neurocrine Biosciences looks meaningfully undervalued, with ongoing growth from Ingrezza, a strong launch for Crenessity, and a promising pipeline. NBIX is looking to grow Ingrezza's market share with ...

SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT®-HD2 study demonstrating an established long-term safety profile ...

Huntington’s disease, also known as Huntington’s chorea and formerly called “Saint Vitus’ dance,” is a rare, hereditary disorder of the central nervous system. It is characterized by jerky movements ...

Abstract: Involuntary movement can be classified into tremor, chorea, athetosis/dystonia, ballismus, myoclonus, or tic. In clinical settings, diagnosing a cause of involuntary movement is generally ...

Austedo (deutetrabenazine) and Ingrezza (valbenazine) are prescription drugs used to treat tardive dyskinesia and chorea associated with Huntington’s disease. Austedo and Ingrezza are not available as ...

At its July 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended against granting marketing authorization in the European Union for ...

Data Add to Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients Treated with INGREZZA for Tardive Dyskinesia Findings Presented at the 2025 American ...

Ever felt nervous to tell your partner something? How about telling them that something … on camera? TikTok is flooded with a new trend where people confess secrets they’ve kept from their significant ...

In 2024, several research and pharmacological advancements were made for tardive dyskinesia, a movement disorder caused by dopamine-blocking medications. Below are some of the highlights of the year.